Genentech Licenses DualityBio’s DUPAC ADC Platform

Companies: DualityBio / Genentech · Deal Type: Licensing Agreement · Platform: DUPAC (Antibody-Drug Conjugate) · Deal Terms: $45M Upfront, Over $1B Potential Milestones · Date: August 28, 2026 Summary Genentech licensed DualityBio’s DUPAC antibody-drug conjugate platform in a deal worth $45 million upfront and more…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

Ipsen Acquires Kartos Therapeutics for Up to $1.75B
Kuva Merger Collapse Forces Lisata Therapeutics Retrenchment
Gilead – $5B Tubulis Acquisition
Scribe Sets Terms for a $100 Million IPO